Immutep (IMMP) has released an update.
Immutep Limited, a biotechnology company, has reported no change in revenue, a 50.7% increase in other income, and a larger net loss of $42.7 million for the fiscal year ended June 30, 2024, compared to the previous year. The increased loss is primarily due to higher R&D and clinical trial costs, despite a rise in interest income and a slight decrease in losses from changes in the fair value of convertible notes. No dividends were declared or paid during the period, and the net tangible asset backing per share increased to 12.5 cents.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
